Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.

Saved in:
Bibliographic Details
Title: Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
Authors: Yau T; The University of Hong Kong, Hong Kong, China., Zagonel V; Oncology Unit 1, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy., Santoro A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.; IRCCS Humanitas Research Hospital-Humanitas Cancer Center, Rozzano, Italy., Acosta-Rivera M; Fundacion de Investigación, San Juan, Puerto Rico., Choo SP; National Cancer Center and Curie Oncology, Singapore., Matilla A; Servicio de Digestivo, Hospital General Universitario Gregorio Marañón, Madrid, Spain.; CIBEREHD, Madrid, Spain., He AR; Georgetown University Hospital, Washington, DC., Cubillo Gracian A; Hospital HM Universitario Sanchinarro, Centro Integral Oncológico Clara Campal (HM-CIOCC), Madrid, Spain.; Departamento de Ciencias Médicas Clínicas, Universidad Camilo José Cela, Madrid, Spain., El-Khoueiry AB; USC Norris Comprehensive Cancer Center, Los Angeles, CA., Sangro B; Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain., Eldawy TE; Sacred Heart Health Systems, Pensacola, FL., Bruix J; BCLC Group, Liver Unit, Hospital Clínic-IDIBAPS, University of Barcelona, CIBEREHD, Barcelona, Spain., Frassineti GL; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Vaccaro GM; Providence Cancer Institute, Portland, OR., Tschaika M; Bristol Myers Squibb, Princeton, NJ., Scheffold C; Exelixis, Inc, Alameda, CA., Koopmans P; Bristol Myers Squibb, Princeton, NJ., Neely J; Bristol Myers Squibb, Princeton, NJ., Piscaglia F; Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Mar 20; Vol. 41 (9), pp. 1747-1757. Date of Electronic Publication: 2022 Dec 13.
Publication Type: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO.22.00972